Stemline Therapeutics announces NEJM publication of ELZONRIS (tagraxofusp) study results
Stemline Therapeutics announced the pivotal trial results of ELZONRIS™ (tagraxofusp), a targeted therapy directed to CD123, in patients with blastic plasmacytoid dendritic cell neoplasm have been published in the April 25 issue of theNew England Journal of Medicine. April 25, 2019